Liquidia Corporation (LQDA) stock analysis
In our weekly check, Liquidia Corporation is graded C (A to F). Of 22 checks on debt, profit, cash flow and trend: 14 pass, warnings: 0, red flags: 8.
About Liquidia Corporation
Liquidia Corporation is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as LQDA.
What our checks show for LQDA
Red flags
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- Weak EPS growth
- The company is losing money: the net margin is -15.1%.
- The price swings a lot: 151% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 94% from a peak. Would you have held through that?
- Recovering from its deepest fall took about 4.3 years.
- The share count grew by 32.4% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
Strengths
- Low debt
- The net margin rose by 254 points over 5 years, to -15.1%.
- The gross margin is 92.7% and has risen by 16.2 points: pricing power is holding.
- Operating cash flow is 2.5x net profit: the profit arrives as real cash.
- Analysts expect earnings per share to grow about 101% a year over the next years.
- Analysts expect revenue to grow about 28.3% a year over the next years.
Similar companies
KNSA · CORT · RPRX
Questions
What grade does Liquidia Corporation (LQDA) have?
In our weekly check, Liquidia Corporation is graded C (A to F). Of 22 checks on debt, profit, cash flow and trend: 14 pass, warnings: 0, red flags: 8. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of LQDA stock?
This week's biggest flags for Liquidia Corporation: Weak interest cover, Weak EPS growth, Thin margins. In total 8 of 22 checks show a warning or a red flag.
What does Liquidia Corporation do?
Liquidia Corporation is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as LQDA.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis